These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26382845)

  • 1. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
    Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
    Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
    You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
    Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
    Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
    Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
    Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
    Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
    Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
    Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated surgeries in invasive lobular breast cancer with preoperative MRI: Role of additional carcinoma in situ and background parenchymal enhancement.
    Preibsch H; Richter V; Bahrs SD; Hattermann V; Wietek BM; Bier G; Kloth C; Blumenstock G; Hahn M; Staebler A; Nikolaou K; Wiesinger B
    Eur J Radiol; 2017 May; 90():181-187. PubMed ID: 28583631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
    Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
    Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.
    Vreemann S; Gubern-Mérida A; Borelli C; Bult P; Karssemeijer N; Mann RM
    PLoS One; 2018; 13(1):e0191399. PubMed ID: 29351560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI background parenchymal enhancement in patients with invasive lobular carcinoma: Endocrine hormonal treatment effect.
    Grubstein A; Rapson Y; Manor M; Yerushalmi R; Gavrieli S; Tamir S; Meshulam S; Atar E; Stemmer SM; Shochat T; Allweis TM
    Breast Dis; 2022; 41(1):317-323. PubMed ID: 35786645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
    Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
    Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
    Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
    Chen JH; Yu H; Lin M; Mehta RS; Su MY
    Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.
    Sutton EJ; Onishi N; Fehr DA; Dashevsky BZ; Sadinski M; Pinker K; Martinez DF; Brogi E; Braunstein L; Razavi P; El-Tamer M; Sacchini V; Deasy JO; Morris EA; Veeraraghavan H
    Breast Cancer Res; 2020 May; 22(1):57. PubMed ID: 32466777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
    Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
    Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Background Parenchymal Enhancement on High-risk Screening MRI and Future Breast Cancer Risk.
    Grimm LJ; Saha A; Ghate SV; Kim C; Soo MS; Yoon SC; Mazurowski MA
    Acad Radiol; 2019 Jan; 26(1):69-75. PubMed ID: 29602724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?
    Feliciano Y; Mamtani A; Morrow M; Stempel MM; Patil S; Jochelson MS
    Ann Surg Oncol; 2017 Jun; 24(6):1492-1498. PubMed ID: 28058550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.